Cleveland Research downgrades Roku (NASDAQ:ROKU) from Buy to Neutral.
Kala Pharmaceuticals Announces Name Change To KALA BIO, Effective August 2, 2023
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today